Fulgent Genetics Confirms Customer Concentration Risk as Largest Client Internalizes Testing in 2026

What happened

Fulgent Genetics' Q4 2025 earnings call outlined ongoing laboratory services growth and accelerated digital pathology investments, but management directly addressed a near-term transition where its largest customer, representing 23% of revenue, is bringing significant testing volume in-house. This development materializes the critical concentration risk highlighted in SEC filings, threatening near-term diagnostics revenue and utilization stability. While the company emphasized progress in therapeutics and AI initiatives to drive future efficiency, operating losses persisted at $(15.4) million in Q3 2025, relying on interest income from a $787.7 million cash balance. The cash cushion provides a temporary buffer, but the planned increase in therapeutics spending to potentially $35-50 million in 2026 could accelerate cash burn if diagnostics growth falters. Investors must now scrutinize whether new customer acquisitions or digital pathology returns can offset this imminent volume loss without eroding margins further.

Implication

The explicit confirmation of customer in-sourcing elevates the bear scenario likelihood, where revenue loss could push operating losses beyond current levels and delay profitability milestones. Management's investments in digital pathology and AI may not yield immediate productivity gains, risking further margin compression amid rising opex from sales team expansion. Fulgent's cash reserve offers downside protection, but accelerated therapeutics spending could shift market perception from a cash-backed turnaround to a cash-burn biotech, pressuring valuation multiples. This news underscores the fragility of the customer base, necessitating rigorous quarterly monitoring of diversification efforts and segment growth sustainability. Ultimately, the stock's rerating hinges on demonstrating rapid volume replacement and cost control, with failure likely triggering a reassessment toward the $18 bear case value.

Thesis delta

The investment thesis that Fulgent can sustain mid-teens diagnostics growth with non-GAAP gross margins above 40% is now under direct pressure from the largest customer's transition, increasing execution risk. Investors must adjust their base case to account for near-term revenue headwinds and require clear evidence of customer diversification or offsetting segment growth to maintain conviction in the turnaround narrative.